Frederick Lundry Locke

Lymphoma response to chimeric antigen receptor T cell therapy is driven by endogenous tumor-reactive CD8⁺ T cells

This study shows that durable CAR-T therapy in lymphoma requires cooperation with endogenous CD8 T cells, and tumors lacking MHC class I or CD58 resist treatment.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma

The paper identifies genomic and transcriptional changes in multiple myeloma cells that drive resistance to anti-BCMA therapies, termed 'plasma cell identity escape'.

RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant B-Cell Lymphoma

Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies

The paper investigates the mutagenic impact of radiotherapy in hematologic malignancies and finds that RT contributes to the ID8 mutational signature, which is associated with treatment resistance and relapse.

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.